Large-scale breast cancer screening trial will compare tomosynthesis and digital mammography.
The Tomosynthesis Mammography Imaging Screening Trial (TMIST) by the ECOG-AGRIN Cancer Research Group is now recruiting medical facilities with an estimated open trial date of mid 2017.
The first large-scale breast cancer screening trial in nearly 25 years has been approved for funding by the National Cancer Institute and will enroll 165,000 asymptomatic women in the U.S. and Canada between ages 45 and 74. The trial is aimed at comparing the incidence of advanced cancers in those screened for four years with digital breast tomosynthesis vs. standard digital mammography.
TMIST will require nearly 100 sites with an estimated four to five women per day to reach the accrual goal in three years, according to a release.
Participation eligibility includes:
• U.S.- or Canada-based medical facility
• Able to provide digital breast tomosynthesis and standard digital mammography in the same location
• Member of a research group in the NCI National Clinical Trials Network (NCTN) either directly or through the NCI Community Oncology Research Program (NCORP)
Interested medical providers can attend one of two available TMIST information sessions at RSNA 2016:
TMIST Satellite Session One
Monday, Nov. 28, 1:30-2:30 in McCormick Place – W470a
TMIST Satellite Session Two
Wednesday, Nov. 30, 11:00-12:00 in McCormick Place – W192b
Preregistration is not required.
Leading Breast Radiologists Discuss the USPSTF Breast Cancer Screening Recommendations
May 17th 2024In recognition of National Women’s Health Month, Dana Bonaminio, MD, Amy Patel, MD, and Stacy Smith-Foley, MD, shared their thoughts and perspectives on the recently updated breast cancer screening recommendations from the United States Preventive Services Task Force (USPSTF).
Contrast-Enhanced Mammography and Dense Breasts: What a New Meta-Analysis Reveals
May 1st 2024The 10-study meta-analysis demonstrated that contrast-enhanced mammography has a 95 percent sensitivity rate and an 81 percent specificity rate for diagnosing suspicious lesions in women with dense breasts.